Clinical Pharmacological Study to Investigate the Effects of Mucosta Ophthalmic Suspension UD2% on Ocular Surface Cells in Patients with Dry Eye - Clinical pharmacological study of Mucosta Ophthalmic Suspension UD2% for Patients with Dry Eye

Otsuka Pharmaceutical Co., Ltd.0 sites15 target enrollmentJune 10, 2016

ConditionsDry eye

Overview

No summary available.

Registry

who.int

Start Date

June 10, 2016

End Date

March 7, 2017

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\.Patients with any anterior segment eye disease such as blepharitis, lagophthalmos, blepharospasm, and iritis, except dry eye (Patients with past history of those diseases are acceptable.) 2\.Patients to whom any ophthalmic drops (all prescription and OCT drugs included) are not able to be discontinued, or expected to be used from the start of the screening until the end of the study period. (Soft santear is acceptable during the screening period.) 3\.Patients who cannot discontinue the use of contact lenses from the start of the screening until the end of the study period 4\.Patients with punctal plugs 5\.Patients who underwent any surgery on the ocular surface within 12 months or intraocular surgery within 3 months prior to the start of the screening 6\.Patients with severe ocular disorder due to Stevens\-Johnson syndrome or ocular pemphigoid 7\.Patients who are pregnant, lactating, or may be pregnant 8\.Patients with hypersensitivity reaction to components of the study drug or test agents used in this study 9\.Patients whom investigatoror sub\-investigatorconsidered not to be able to include the study because of prior or complicated systemic disease 10\.Patients participating in another clinical study or trial 11\.Others who areconsidered inappropriate for the study by investigatoror sub\-investigator